All In Biotech

Drug Trial Radar · NCT07217067

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Sep 9, 2027

Study completion Sep 9, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

Conditions

  • Atrial Fibrillation

Interventions

  • PKN605Drug

    PKN605 is an oral formulation

  • PlaceboOther

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Atrial fibrillation burden from ECG patch monitorsTime frame: 24 weeks

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • Cardiology Associates of North MS

    Tupelo, Mississippi · Recruiting

  • Cooper University Hospital

    Camden, New Jersey · Recruiting

  • Weill Cornell Medical Center

    New York, New York · Recruiting

  • Duke Univ Medical Center

    Durham, North Carolina · Recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • Swedish Heart and Vascular Clinic

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Calgary, Alberta, Canada · Recruiting

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada · Recruiting

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Novartis Investigative Site

    Hamilton, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Newmarket, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Québec, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Sherbrooke, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Xi'an, China · Recruiting

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China · Recruiting

  • Novartis Investigative Site

    Bad Homburg, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Recruiting

  • Novartis Investigative Site

    Groningen, Netherlands · Recruiting

  • Novartis Investigative Site

    Veldhoven, Netherlands · Recruiting

  • Novartis Investigative Site

    Arnhem, Gelderland, Netherlands · Recruiting

  • Novartis Investigative Site

    Maastricht, Limburg, Netherlands · Recruiting

  • Novartis Investigative Site

    Delft, South Holland, Netherlands · Withdrawn

  • Novartis Investigative Site

    Goes, Zeeland, Netherlands · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Liverpool, United Kingdom · Withdrawn

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

  • Novartis Investigative Site

    Brighton, East Sussex, United Kingdom · Recruiting

  • Novartis Investigative Site

    Newcastle upon Tyne, Tyne and Wear, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.